Replacing Alteplase with Tenecteplase: Is the Time Ripe?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Thrombolysis for acute ischemic stroke has predominantly been with alteplase for over a quarter of a century. In recent years, with trials showing evidence of higher rates of successful reperfusion, similar safety profile and efficacy of tenecteplase (TNK) as compared to alteplase, TNK has now emerged as another potential choice for thrombolysis in acute ischemic stroke. In this review, we will focus on these recent advances, aiming: (1) to provide a brief overview of thrombolysis in stroke; (2) to provide comparisons between alteplase and TNK for clinical, imaging, and safety outcomes; (3) to focus on key subgroups of interest to understand if there is an advantage of using TNK over alteplase or vice-versa, to review available evidence on role of TNK in intra-arterial thrombolysis, as bridging therapy and in mobile stroke units; and (4) to summarize what to expect in the near future from recently completed trials and propose areas for future research on this evolving topic. We present compelling data from several trials regarding the safety and efficacy of TNK in acute ischemic stroke along with completed yet unpublished trials that will help provide insight into these unanswered questions.
Abstract
Thrombolysis for acute ischemic stroke has predominantly been with alteplase for over a quarter of a century. In recent years, with trials showing evidence of higher rates of successful reperfusion, similar safety profile and efficacy of tenecteplase (TNK) as compared to alteplase, TNK has now emerged as another potential choice for thrombolysis in acute ischemic stroke. In this review, we will focus on these recent advances, aiming: (1) to provide a brief overview of thrombolysis in stroke; (2) to provide comparisons between alteplase and TNK for clinical, imaging, and safety outcomes; (3) to focus on key subgroups of interest to understand if there is an advantage of using TNK over alteplase or vice-versa, to review available evidence on role of TNK in intra-arterial thrombolysis, as bridging therapy and in mobile stroke units; and (4) to summarize what to expect in the near future from recently completed trials and propose areas for future research on this evolving topic. We present compelling data from several trials regarding the safety and efficacy of TNK in acute ischemic stroke along with completed yet unpublished trials that will help provide insight into these unanswered questions.
참고문헌 (37)
- Haley EC Jr, "Phase IIB", III trial of tenecteplase in acute ischemic stroke : results of a prematurely terminated randomized clinical trial, 2010, pp.41, 707~711
- Coutts SB, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion", Stroke, 46, pp.769~774 (2015)
- Kheiri B, "Tenecteplase versus alteplase for management of acute ischemic stroke : a pairwise and network meta-analysis of randomized clinical trials", J Thromb Thrombolysis, 46, pp.440~450 (2018)
- Katsanos AH, "Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions : systematic review and meta-analysis", Stroke, 52, pp.308~312 (2021)
- Logallo N, "Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial", Lancet Neurol, 16, pp.781~788 (2017)
- Zhou Z, "Low-dose vs standard-dose alteplase in acute lacunar ischemic stroke : the ENCHANTED trial", Neurology, 96, pp.e1512~e1526 (2021)
- Burgos AM, "Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke : meta-analysis of 5 randomized trials", Stroke, 50, pp.2156~2162 (2019)
- Menon BK, "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial", Lancet, 400, pp.161~169 (2022)
- Sajobi T, "AcT trial : protocol for a pragmatic registry-linked randomized clinical trial", Stroke Vasc Interv Neurol, 2, pp.e000447~ (2022)
- Kvistad CE, "Safety and outcomes of tenecteplase in moderate and severe ischemic stroke", Stroke, 50, pp.1279~1281 (2019)
- Bivard A, "Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne mobile stroke unit (TASTE-A): a phase 2, randomised, open-label trial", Lancet Neurol, 21, pp.520~527 (2022)
- Kvistad CE, "Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, noninferiority trial", Lancet Neurol, 21, pp.511~519 (2022)
- Bivard A, "Tenecteplase in ischemic stroke offers improved recanalization : analysis of 2 trials", Neurology, 89, pp.62~67 (2017)
- Campbell BCV, "Tenecteplase versus alteplase before thrombectomy for ischemic stroke", N Engl J Med, 378, pp.1573~1582 (2018)
- Campbell BCV, "Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke : the EXTEND-IA TNK part 2 randomized clinical trial", JAMA, 323, pp.1257~1265 (2020)
- Thomalla G, "MRI-guided thrombolysis for stroke with unknown time of onset", N Engl J Med, 379, pp.611~622 (2018)
- Ahmed HK, "Clinical outcomes and safety profile of tenecteplase in wake-up stroke", Acta Neurol Scand, 142, pp.475~479 (2020)
- Roaldsen MB, "Tenecteplase in wake-up ischemic stroke trial : protocol for a randomized-controlled trial", Int J Stroke, 16, pp.990~994 (2021)
- "ESOC 2022 – Late breaking science, ongoing trials & young stroke physicians and researchers", Eur Stroke J, 7(1 Suppl), pp.546~588 (2022)
- Rønning OM, "Tenecteplase versus alteplase between 3 and 4.5 hours in low national institutes of health stroke scale", Stroke, 50, pp.498~500 (2019)
- Bluhmki E, "Alteplase for acute ischemic stroke in patients aged >80 years : pooled analyses of individual patient data", Stroke, 51, pp.2322~2331 (2020)
- Yogendrakumar V, "Safety and efficacy of tenecteplase in older patients with large vessel occlusion : a pooled analysis of the EXTEND-IA TNK trials", Neurology, 98, pp.e1292~e1301 (2022)
- Alemseged F, "Tenecteplase vs alteplase before endovascular therapy in basilar artery occlusion", Neurology, 96, pp.e1272~e1277 (2021)
- Renú A, "Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke : the choice randomized clinical trial", JAMA, 327, pp.826~835 (2022)
- Georgiadis AL, "Intra-arterial tenecteplase for treatment of acute ischemic stroke : feasibility and comparative outcomes", J Neuroimaging, 22, pp.249~254 (2012)
- Pierre Seners, "Recanalization before Thrombectomy in Tenecteplase vs. Alteplase-Treated Drip-and-Ship Patients", 대한뇌졸중영문학회지, 21(1), pp.105~107 (2019), 대한뇌졸중학회[DOI]
- Gerschenfeld G, "Functional outcome, recanalization, and hemorrhage rates after large vessel occlusion stroke treated with tenecteplase before thrombectomy", Neurology, 97, pp.e2173~e2184 (2021)
- Singh N, "Understanding physician and patient preferences for thrombolysis in ischemic stroke eligible for endovascular thrombectomy", Stroke Vasc Interv Neurol, 2, pp.e000218~ (2022)
- "Late breaking abstracts", J Cereb Blood Flow Metab, 42(1_suppl), pp.285~324 (2022)
- Powers WJ, "Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2019, pp.50, e344~e418
- Berge E, "European Stroke Organisation(ESO)guidelines on intravenous thrombolysis for acute ischaemic stroke", Eur Stroke J, 6, pp.I~LXII (2021)
- Boulanger JM, "Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018", Int J Stroke, 13, pp.949~984 (2018)
- Mahawish K, "Switching to tenecteplase for stroke thrombolysis : real-world experience and outcomes in a regional stroke network", Stroke, 52, pp.e590~e593 (2021)
- Parsons M, "A randomized trial of tenecteplase versus alteplase for acute ischemic stroke", N Engl J Med, 366, pp.1099~1107 (2012)
- Roaldsen MB, "Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial", Lancet Neurol, 22, pp.117~126 (2023)
- Van De Werf F, "Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction : the ASSENT-2 double-blind randomised trial", Lancet, 354, pp.716~722 (1999)
- Huang X, "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study", Lancet Neurol, 14, pp.368~376 (2015)